- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04267068
Single Session Intervention to Prevent Common Mental Disorders and Among College Students
November 4, 2020 updated by: University of Nevada, Reno
The present study aims to determine the effect of presenting psychoeducation emphasizing "growth-mindset," and information on depression and anxiety symptom severity.
The investigators hypothesize that psychoeducation emphasizing that mental health is malleable will increase the participant's engagement with risk factors outlined in the intervention
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
Depression and anxiety disorders (or common mental disorders; CMDs) are increasingly common among college students, with rates comparable to the general population.
As such, brief, scalable and transdiagnostic prevention efforts targeting CMDs are needed.
In order to address this need, this study aims to evaluate the impact of a single session intervention (SSI) utilizing growth mindset (GM) on CMD symptom severity and investigate the mediating role of changes in modifiable risk factors in the relationship between intervention and CMD symptom reduction.
The intervention will adapt existing GM interventions for college students to engage mechanisms in the prevention and management of common mental disorders including engagement in modifiable risk factors.
College students will be randomly assigned to complete either a GM intervention or a psychoeducation control.
Study Type
Interventional
Enrollment (Actual)
375
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Nevada
-
Reno, Nevada, United States, 89557
- University of Nevada, Reno
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
17 years to 26 years (ADULT, CHILD)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Age 17-26
- College student at the University of Nevada, Reno
Exclusion Criteria:
- Under the age of 17, over the age of 26
- Participated in pilot study
- Not a college student at the University of Nevada, Reno
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: PREVENTION
- Allocation: RANDOMIZED
- Interventional Model: FACTORIAL
- Masking: TRIPLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
EXPERIMENTAL: Intervention
Online growth mindset interactive article followed by equal length interactive article describing the relationship between modifiable risk factors (MRF) and mental health outcomes
|
15 minute interactive article describing neuroplasticity followed by 15 minute interactive article describing modifiable risk factors for depression and anxiety
|
|
ACTIVE_COMPARATOR: Control
Online daily activity scheduling interactive article (control)
|
30 minute interactive article describing symptoms of depression and anxiety, common concerns of college student
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Patient Health Questionnaire (PHQ-9; Kroenke, Spitzer & Williams, 2001)
Time Frame: 6 months
|
9-item questionnaire associated containing one item for each symptom of MDD as specified by the DSM.
Items consist of a 4-point Likert scale (0="Not at all" to 3="Nearly every day").
Minimum score is 0, maximum score is 27.
Higher scores indicate greater depression severity.
|
6 months
|
|
Generalized Anxiety Disorder-7 (GAD-7; Spitzer, Kroenke, Williams & Lowe, 2006)
Time Frame: 6 months
|
7-item scale, common, brief measure of anxiety symptom severity.
Items consist of a 4-point Likert scale (0="Not at all" to 3="Nearly every day").
Minimum score is 0, maximum score is 21.
Higher scores indicate greater anxiety symptom severity.
|
6 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Anthony Papa, Ph.D., University of Nevada, Reno
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ACTUAL)
August 5, 2019
Primary Completion (ACTUAL)
July 13, 2020
Study Completion (ACTUAL)
July 13, 2020
Study Registration Dates
First Submitted
November 5, 2019
First Submitted That Met QC Criteria
February 10, 2020
First Posted (ACTUAL)
February 12, 2020
Study Record Updates
Last Update Posted (ACTUAL)
November 6, 2020
Last Update Submitted That Met QC Criteria
November 4, 2020
Last Verified
November 1, 2020
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 1219218
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.